1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy

Pas encore traduit Pas encore traduit
Cet article n'a pas de résumé
Epistemonikos ID: ef2ec3e807cdc6693698066d364236e4c4b457bc
First added on: Feb 16, 2025